PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness

Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2 mutant cancers through a synthetic lethal interaction. PARPi exert their therapeutic effects mainly through the blockade of single-stranded DNA damage repair, which leads to the accumula...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Shen, Jianfeng, Zhao, Wei, Ju, Zhenlin, Wang, Lulu, Peng, Yang, Labrie, Marilyne, Yap, Timothy A., Mills, Gordon B., Peng, Guang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6588002/
https://ncbi.nlm.nih.gov/pubmed/30482774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-1003
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak